Anesiva, Inc. (ANSV)


Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has two drug candidates in development for multiple pain-related indications. An NDA has been filed for the most advanced product, Zingo. The second product in the pipeline, Adlea (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to

Contact Information

650 Gateway Boulevard
South San Francisco, CA 94080

tel: 650-624-9600
fax: 650-624-7540


Investor Relations



Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $151.6M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.